EM2404H “New Treatments for Anemia, Ischemia, and Cancer Emerging from Studies of von Hippel-Lindau Disease” (IM GR-041924)

Purpose and Overview

This lecture will provide a historical overview of von Hippel-Lindau disease and how studies of this disorder led to the discovery of a molecular circuit used by mammalian cells to sense oxygen availability and transduce that information into changes in gene expression. This lecture will also describe how this knowledge has created opportunities for developing new treatments for a diverse set of diseases.

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Understand how, biochemically, mammalian cells sense and adapt to changes in oxygen at the level of gene transcription.
  • Understand the critical role that inactivation of the von Hippel-Lindau tumor suppressor protein plays in the development of clear cell renal cell carcinoma, the most common form of kidney cancer
  • Appreciate the rationales for developing HIF antagonists and agonists for the treatment of different human diseases
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
Course expires: 

Photo: First Last, M.D.William G. Kaelin Jr., MD
Sidney Farber Professor of Medicine
Dana-Farber Cancer Institute & Harvard Medical School

Available Credit

  • 1.00 AMA


Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome